Skip to Main Content

Markus Müschen, MD, PhD

Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Director, Center of Molecular and Cellular Oncology; Chief, Cellular and Molecular Oncology

Research Summary

To prevent production of harmful autoantibodies and autoimmune disease, autoreactive B-cells are eliminated by a process termed negative selection. In recent years, our laboratory established new conceptual frameworks for the understanding of B-cell signaling mechanisms and negative selection. Contrary to established dogma, these mechanisms are not only active in preventing autoimmune disease but also represent an emerging class of therapeutic targets in malignant B-cell tumors.

  • We discovered regulation of energy-abundance as the central determinant of negative B-cell-selection: Hyperactivation of kinases downstream of an autoreactive B-cell receptor induces ATP-depletion and energy stress.
  • Studying changes of energy-metabolism during B-cell transformation, we discovered that glucose carbon-flux was diverted in way that left transformed B-cells uniquely vulnerable to inhibition of PP2A, an enzyme that coordinates glycolytic flux with antioxidant protection.
  • We discovered that changes in cell-size are orchestrated by BCL6 and MYC. Opposed by MYC, BCL6 decreases cell-size by transcriptionally repressing glucose-uptake in favor of autophagy.
  • Tracking mechanisms of leukemia-initiation in 1,100 patients, we developed the paradigm of ‘pathway convergence’. Only mutations that converged on one central pathway promoted leukemia-progression. Genetic reactivation of divergent (suppressed) pathways engaged conflicting biochemical and transcriptional programs and subverted leukemia-development. Pharmacological pathway-reactivation to create a diverse signaling-environment represents a novel strategy to prevent leukemia-progression.
  • Studying biophysical mechanisms of B-cell activation, we discovered the short endosomal protein IFITM3 as central scaffold for lipid-raft assembly and surface-expression of rafts-associated receptors. Membrane-recruitment of IFITM3 was essential for the initiation of PI3K-signaling, antibody affinity maturation and oncogenic B-cell transformation.


    Extensive Research Description

    Dr. Markus Müschen is the Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and was appointed Director of the CMCO in 2020. He obtained his MD degree in Biochemistry with Helmut Sies (summa cum laude) from the Heinrich-Heine-Universität in Düsseldorf, completed his residency in Hematology-Oncology with Volker Diehl and his MD-PhD with Martin Krönke in Immunology at the University of Cologne, Germany. Since 2009, the Müschen laboratory has established new conceptual frameworks for the understanding of B-cell signaling and energy metabolism and how defects in these mechanisms contribute to autoimmunity and B-cell transformation. Influenced by his postdoctoral training in basic immunology (Klaus Rajewsky and Ralf Küppers) and cancer genetics (Janet D. Rowley), Dr. Müschen is particularly interested in signal transduction pathways that change the clinical trajectory of human B-cell malignancies and B-cell driven autoimmune diseases. To generate hypotheses and for target discovery, his laboratory builds on clinical outcome predictors: in collaboration with multiple study teams across the US, his group developed and validated phenotypic biomarkers of favorable and poor clinical outcomes in B-cell malignancies and integrated these markers into models of oncogenic signaling pathways. As PI of the NCI CTEP ‘Human hematopoiesis and leukemia PDX’ program, his laboratory developed PDX resources to model B-cell malignancies based on patient-derived cells and cord blood-based humanized mouse models to study mechanisms of human B-lymphopoiesis in vivo.

    In 2010, Dr. Müschen joined the University of California San Francisco (UCSF) as full professor with tenure and served as Program Leader of the Hematological Malignancies Program at the UCSF Comprehensive Cancer Center. He is currently a Howard Hughes Medical Institute (HHMI) Faculty Scholar and supported by an NCI Outstanding Investigator Award (R35). The Müschen laboratory consists of 18 trainees and staff. So far, 16 of his former trainees have become tenured or tenure-track faculty in academic research at institutions including UCSF, Imperial College, University of Pennsylvania, Stanford University, WEHI, TU Munich, SIBS Shanghai, Penn State and University of Cologne. At Yale University, Dr. Müschen serves as Director of the Center of Molecular and Cellular Oncology and as a mentor for six junior faculty.

    Coauthors

    Research Interests

    Antibody Affinity; Antibody Specificity; Arthritis, Rheumatoid; Autoimmune Diseases; Autophagy; B-Lymphocytes; Cell Adhesion; Cell Communication; Cell Cycle; Cell Division; DNA Damage; Endocytosis; Energy Metabolism; Genes, Immunoglobulin; Hematologic Diseases; Immunity; Immunologic Deficiency Syndromes; Leukemia; Lymphocyte Cooperation; Lymphocyte Activation; Lymphoma; Metabolism; Oxygen Consumption; Phosphorylation; Preleukemia; Receptor Aggregation; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell; Gene Rearrangement; Signal Transduction; Leukemia, B-Cell; Lymphoma, T-Cell; Cellular Senescence; Cell Death; Antigen Presentation; Oxidative Stress; Molecular Mimicry; Cell Respiration; Cell Lineage; Cell Size; Carbohydrate Metabolism; Lipid Metabolism; Neoplasms, Plasma Cell; Metabolome; Clonal Evolution; Clonal Selection, Antigen-Mediated; Cellular Reprogramming; Oncogene Addiction; Cell Competition

    Selected Publications

    • Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell TransformationChan L, Hurtz C, Leveille E, Kume K, Robinson M, Geng H, Cosgun K, Müschen M. Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation Blood 2021, 138: 792-792. DOI: 10.1182/blood-2021-148653.
    • Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid MalignanciesLee J, Robinson M, Ma N, Kume K, Artadji D, Sadras T, Cosgun K, Geng H, Paietta E, Buchner M, Vaidehi N, Weinstock D, Müschen M. Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies Blood 2021, 138: 355-355. DOI: 10.1182/blood-2021-149189.
    • Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell TransformationLee J, Robinson M, Ma N, Sadras T, Cosgun K, Chan L, Kume K, Thomas-Tikhonenko A, Weinstock D, Diamond M, Vaidehi N, Müschen M. Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation Blood 2021, 138: 868-868. DOI: 10.1182/blood-2021-149646.
    • Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic LeukemiaChan L, Murakami M, Hurtz C, Kume K, Lee J, Cosgun K, Geng H, Izraeli S, Weinstock D, Müschen M. Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood 2021, 138: 616-616. DOI: 10.1182/blood-2021-149773.
    • Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinal Center B-Cell MalignanciesKume K, Lee J, Chan L, Robinson M, Cosgun K, Meffre E, Müschen M. Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinal Center B-Cell Malignancies Blood 2021, 138: 2267-2267. DOI: 10.1182/blood-2021-149806.
    • Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell MalignanciesCosgun K, Robinson M, Chan L, Hur M, Leveille E, Song J, Chan W, Müschen M. Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor-Suppression in B-Cell Malignancies Blood 2021, 138: 29-29. DOI: 10.1182/blood-2021-148597.
    • Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunitiesXu L, Chen Y, Huang Y, Sandanaraj E, Yu J, Lin R, Dakle P, Ke X, Chong Y, Koh L, Mayakonda A, Nacro K, Hill J, Huang M, Gery S, Lim S, Huang Z, Xu Y, Chen J, Bai L, Wang S, Wakimoto H, Yeo T, Ang B, Müschen M, Tang C, Tan T, Koeffler P. Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities Cancer Research 2021, 81: 2123-2123. DOI: 10.1158/1538-7445.am2021-2123.
    • Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and LeukemogenesisLee J, Xiao G, Cosgun K, Geng H, Ma N, Chan L, Kume K, Nix M, Chen Z, Chen C, Chen J, Khairnar V, Wiita A, Thomas-Tikhonenko A, Farzan M, Diamond M, Jung J, Vaidehi N, Müschen M. Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis Blood 2019, 134: 2782-2782. DOI: 10.1182/blood-2019-127615.
    • Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALLXiao G, Kume K, Geng H, Han T, Klemm L, Müschen M. Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL Blood 2019, 134: 3785-3785. DOI: 10.1182/blood-2019-128719.
    • Autonomous Ca2+ Oscillations Reflect Oncogenic Signaling in B-ALL CellsKume K, Chen L, Lee J, Müschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic Signaling in B-ALL Cells Blood 2019, 134: 1253-1253. DOI: 10.1182/blood-2019-130708.
    • Signaling Input from Divergent Pathways Subverts Malignant B-Cell TransformationChan L, Murakami M, Caesar R, Hurtz C, Kume K, Sadras T, Shojaee S, Pölönen P, Ugale A, Lee J, Cosgun K, Geng H, Heinäniemi M, Lohi O, Wiita A, Izraeli S, Weinstock D, Müschen M. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation Blood 2019, 134: 3944-3944. DOI: 10.1182/blood-2019-130774.
    • Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell TransformationCosgun K, Deb G, Yang X, Xiao G, Sadras T, Lee J, Chan L, Kume K, Yang L, Geng H, Chan J, Song J, Jumaa H, Polson A, Clevers H, Müschen M. Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation Blood 2019, 134: 748-748. DOI: 10.1182/blood-2019-127263.
    • Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-SignalingLee J, Kume K, Chen Z, Xiao G, Cosgun K, Chen L, Chan L, Klemm L, Chen C, Ma N, Chan W, Forman S, Zammarchi F, Van Berkel P, Melnick A, Ngo V, Geng H, Luger S, Litzow M, McManus M, Vaidehi N, Paietta E, Meffre E, Weinstock D, Müschen M. Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling Blood 2019, 134: 393-393. DOI: 10.1182/blood-2019-131270.
    • Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell MalignanciesSadras T, Martin M, Kim-Sing L, Cutler J, Lenz G, Knapp A, Ghergus D, Delmotte F, Schleiss C, Korganow A, Soulas-Sprauel P, Chen Z, Pandey A, Weinstock D, Jumaa H, Meffre E, Martin T, Müschen M. Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies Blood 2019, 134: 295-295. DOI: 10.1182/blood-2019-128999.
    • Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library ScreeningQin X, Su R, Yang L, Chan A, Deng X, Qing Y, Klemm L, Müschen M, Chen C, Chen J. Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening Blood 2019, 134: 1465-1465. DOI: 10.1182/blood-2019-129849.
    • Rationale for Targeting BCL6 in MLL-Rearranged B-ALLChan L, Hurtz C, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Armstrong S, Ernst P, Melnick A, Milne T, Müschen M. Rationale for Targeting BCL6 in MLL-Rearranged B-ALL Blood 2019, 134: 1239-1239. DOI: 10.1182/blood-2019-131565.
    • Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug ResistanceSu R, Dong L, Li Y, Han L, Gao M, Wunderlich M, Deng X, Li H, Gao L, Li C, Robison S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Huang Y, Li W, Shen C, Sun J, Prakash K, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen M, Müschen M, Marcucci G, Ravi S, Li L, Yang C, Li Z, Mulloy J, Wei M, Horne D, Chen J. Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance Blood 2019, 134: 233-233. DOI: 10.1182/blood-2019-124535.
    • Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper FunctionsPan L, Hong C, Xiao G, Geng H, Wang S, Müschen M. Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions Blood 2019, 134: 746-746. DOI: 10.1182/blood-2019-125171.
    • Novel BAFF‐R CAR T‐cell Therapy for CD19 Antigen‐loss Relapsed B Cell TumorsKwak L, Qin H, Dong Z, Wang X, Cheng W, Smith D, Song J, Aldoss I, Muschen M, Forman S. Novel BAFF‐R CAR T‐cell Therapy for CD19 Antigen‐loss Relapsed B Cell Tumors Hematological Oncology 2019, 37: 165-166. DOI: 10.1002/hon.123_2629.
    • Autonomous Ca2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and ProliferationKume K, Chen L, Lee J, Muschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation Blood 2018, 132: 1373-1373. DOI: 10.1182/blood-2018-99-117315.
    • CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell MalignanciesLee J, Kume K, Chen Z, Xiao G, Cosgun K, Chan L, Chen C, Pillai R, Chan W, Forman S, Kwak L, Zammarchi F, Van Berkel P, Weinstock D, Melnick A, Ngo V, Geng H, Luger S, Litzow M, Belot A, Uzel G, McManus M, Paietta E, Meffre E, Muschen M. CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies Blood 2018, 132: 776-776. DOI: 10.1182/blood-2018-99-117553.
    • Autoimmunity Checkpoints As Therapeutic Targets in B-Cell MalignanciesChen Z, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies Blood 2018, 132: 1587-1587. DOI: 10.1182/blood-2018-99-113674.
    • Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALLZhu Y, He X, Dong H, Sun J, Wang H, Zhang L, Miao Y, Jin J, Shen Y, Chen J, Muschen M, Chen C, Konopleva M, Sun W, Zhang B, Kuo Y, Carlesso N, Marcucci G, Li L. Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL Blood 2018, 132: 892-892. DOI: 10.1182/blood-2018-99-115139.
    • Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor SignalingChan L, Hurtz C, Geng H, Auer F, Chen Z, Xiao G, Lee J, Cosgun K, Ye B, Muschen M. Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling Blood 2018, 132: 1336-1336. DOI: 10.1182/blood-2018-99-115514.
    • Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic LeukemiaCosgun K, Hendriks R, Dickins R, Heisterkamp N, Muschen M. Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia Blood 2018, 132: 570-570. DOI: 10.1182/blood-2018-99-115522.
    • Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell MalignanciesSadras T, Cutler J, Aguade-Gorgorio J, Chen Z, Cosgun K, Pandey A, Muschen M. Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies Blood 2018, 132: 3922-3922. DOI: 10.1182/blood-2018-99-116954.
    • Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell MalignanciesCosgun K, Deb G, Yang X, Xiao G, Sadras T, Auer F, Lee J, Abarientos A, Mangolini M, Aghajanirefah A, Geng H, Jumaa H, Polson A, Clevers H, Muschen M. Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies Blood 2018, 132: 547-547. DOI: 10.1182/blood-2018-99-116956.
    • DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic LeukemiaBraun M, Ecker V, Neumayer T, Muschen M, Ruland J, Buchner M. DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia Blood 2018, 132: 2857-2857. DOI: 10.1182/blood-2018-99-117052.
    • Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell TumorsQin H, Dong Z, Wang X, Cheng W, Smith D, Song J, Aldoss I, Muschen M, Forman S, Kwak L. Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors Blood 2018, 132: 1411-1411. DOI: 10.1182/blood-2018-99-117513.
    • Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic LeukemiaChan L, Shojaee S, Hurtz C, Auer F, Chen Z, Cosgun K, Geng H, Sadras T, White D, Muschen M. Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia Blood 2018, 132: 568-568. DOI: 10.1182/blood-2018-99-115536.
    • SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic LeukemiaEcker V, Braun M, Neumayer T, Muschen M, Ruland J, Buchner M. SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia Blood 2018, 132: 894-894. DOI: 10.1182/blood-2018-99-117053.
    • IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell TransformationLee J, Geng H, Dinson D, Xiao G, Cosgun K, Chan L, Chen Z, Farzan M, Jung J, Wiita A, Muschen M. IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation Blood 2018, 132: 552-552. DOI: 10.1182/blood-2018-99-117472.
    • Autoimmunity Checkpoints in B-Cell Lineage ALLMüschen M. Autoimmunity Checkpoints in B-Cell Lineage ALL Clinical Lymphoma Myeloma & Leukemia 2018, 18: s51-s52. DOI: 10.1016/j.clml.2018.06.054.
    • 1028 B-Cell Identity as A Metabolic Barrier Against Malignant TransformationMüschen M. 1028 B-Cell Identity as A Metabolic Barrier Against Malignant Transformation Experimental Hematology 2018, 64: s36-s37. DOI: 10.1016/j.exphem.2018.06.033.
    • 3021 LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B CellsCosgun K, Yang X, Mangolini M, Xiao G, Abarientos A, Aghajanirefah A, Klemm L, Sadras T, Geng H, Yang L, Song Q, Zeng D, Zeng D, Jumaa H, Polson A, Clevers H, Muschen M. 3021 LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B Cells Experimental Hematology 2018, 64: s59-s60. DOI: 10.1016/j.exphem.2018.06.206.
    • 3154 T-Cell Associated ZAP70 Kinase Contributes to B-Cell Receptor Signaling in Malignant LymphopoiesisSadras T, Chen Z, Klemm L, Cosgun K, Müschen M. 3154 T-Cell Associated ZAP70 Kinase Contributes to B-Cell Receptor Signaling in Malignant Lymphopoiesis Experimental Hematology 2018, 64: s99. DOI: 10.1016/j.exphem.2018.06.137.
    • Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignanciesLee J, Geng H, Chen Z, Xiao G, Cosgun K, Zammarchi F, Berkel P, Melnick A, Paietta E, Muschen M. Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Cancer Research 2018, 78: 2983-2983. DOI: 10.1158/1538-7445.am2018-2983.
    • Abstract 368: B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignanciesXiao G, Chen Z, Chan L, Braas D, Graeber T, Geng H, Jumaa H, Jiang X, Müschen M. Abstract 368: B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies Cancer Research 2018, 78: 368-368. DOI: 10.1158/1538-7445.am2018-368.
    • Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignanciesCosgun K, Hecht A, Yang X, Mangolini M, Aghajanirefah A, Xiao G, Sadras T, Chen Z, Klemm L, Geng H, Hong C, Song Q, Zeng D, Jumaa H, Zeng D, Clevers H, Muschen M. Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies Cancer Research 2018, 78: 4515-4515. DOI: 10.1158/1538-7445.am2018-4515.
    • Abstract 5469: RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibitionChan L, Shojaee S, Hurtz C, Caeser R, Xiao G, Geng H, Kornblau S, Muschen M. Abstract 5469: RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibition Cancer Research 2018, 78: 5469-5469. DOI: 10.1158/1538-7445.am2018-5469.
    • Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell MalignanciesChen Z, Hecht A, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies Blood 2017, 130: 718-718. DOI: 10.1182/blood.v130.suppl_1.718.718.
    • PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying LactonasesXiao G, Hong C, Geng H, Muschen M. PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases Blood 2017, 130: 882-882. DOI: 10.1182/blood.v130.suppl_1.882.882.
    • Abstract 1524: BCL6 modulates the TP53 and STAT pathways in gliomaChen Y, Xu L, Dutra-Clarke M, Mayakonda A, Lin D, Koh L, Chong Y, Sandanaraj E, Madan V, Yang H, Doan N, Said J, Yong W, Müschen M, Ang B, Tang C, Breunig J, Koeffler P. Abstract 1524: BCL6 modulates the TP53 and STAT pathways in glioma Cancer Research 2017, 77: 1524-1524. DOI: 10.1158/1538-7445.am2017-1524.
    • Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic targetXu L, CHEN Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff S, Doan N, Said J, Yong W, Yang H, Ding L, Jiang Y, Tyner J, Ching J, Kovalik J, Müschen M, Breunig J, Lin D, Koeffler P. Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic target Cancer Research 2017, 77: 2569-2569. DOI: 10.1158/1538-7445.am2017-2569.
    • Abstract 93: Transcriptional control of glucocorticoid responses in leukemiaChan L, Chen Z, Xiao G, Lee J, Cosgun K, Geng H, Cazzaniga V, Schjerven H, Dickins R, Muschen M. Abstract 93: Transcriptional control of glucocorticoid responses in leukemia Cancer Research 2017, 77: 93-93. DOI: 10.1158/1538-7445.am2017-93.
    • V(D)J RecombinationMüschen M. V(D)J Recombination 2017, 4773-4777. DOI: 10.1007/978-3-662-46875-3_6171.
    • Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell TransformationChan L, Chen Z, Xiao G, Lee J, Geng H, Christian H, Cazzaniga V, Cazzaniga G, Dickins R, Müschen M. Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation Blood 2016, 128: 437-437. DOI: 10.1182/blood.v128.22.437.437.
    • BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell TransformationChan L, Hurtz C, Xiao G, Shojaee S, Caeser R, Geng H, Melnick A, Müschen M. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation Blood 2016, 128: 438-438. DOI: 10.1182/blood.v128.22.438.438.
    • Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic LeukemiaHurtz C, Chan L, Ballabio E, Willman C, Carroll W, Armstrong S, Ernst P, Melnick A, Milne T, Müschen M. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia Blood 2016, 128: 907-907. DOI: 10.1182/blood.v128.22.907.907.
    • IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell MalignanciesLee J, Geng H, Cosgun K, Chan L, Chen Z, Park E, Klemm L, Bailey C, Müschen M. IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies Blood 2016, 128: 2738-2738. DOI: 10.1182/blood.v128.22.2738.2738.
    • mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALLGotesman M, Vo T, Mallya S, Zhang Q, Shi C, Müschen M, Weinstock D, Mullighan C, Tasian S, Konopleva M, Fruman D. mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL Blood 2016, 128: 2763-2763. DOI: 10.1182/blood.v128.22.2763.2763.
    • Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic LeukemiaChan L, Lee J, Cosgun K, Geng H, Xiao G, Chen Z, Ernst T, Hochhaus A, Müschen M. Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2016, 128: 2771-2771. DOI: 10.1182/blood.v128.22.2771.2771.
    • Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose MetabolismChen Z, Geng H, Klemm L, Chan L, Daniel B, Alexander W, Willman C, Müschen M. Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism Blood 2016, 128: 4069-4069. DOI: 10.1182/blood.v128.22.4069.4069.
    • Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted TreatmentsTeppo S, Mehtonen J, Eldfors S, Heckman C, Müschen M, Heinäniemi M, Lohi O. Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments Blood 2016, 128: 4077-4077. DOI: 10.1182/blood.v128.22.4077.4077.
    • CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell MalignanciesLee J, Geng H, Chen Z, Klemm L, Cosgun K, Xiao G, Masouleh B, Hurtz C, Parekh S, Kornblau S, Melnick A, Abbas A, Paietta E, Müschen M. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies Blood 2016, 128: 4088-4088. DOI: 10.1182/blood.v128.22.4088.4088.
    • PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic LeukemiaXiao G, Chen Z, Daniel B, Chan L, Geng H, Jiang X, Müschen M. PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia Blood 2016, 128: 1056-1056. DOI: 10.1182/blood.v128.22.1056.1056.
    • Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemiaKöhrer S, Seyfried F, Debatin K, Müschen M, Meyer L, Davis R, Burger J. Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemia Klinische Pädiatrie 2016, 228 DOI: 10.1055/s-0036-1582492.
    • Abstract PR11: Targeted engagement of B cell autoimmunity checkpoints to overcome drug resistance in pediatric Ph-like ALLChen Z, Geng H, Lowell C, Hunger S, Müschen M. Abstract PR11: Targeted engagement of B cell autoimmunity checkpoints to overcome drug resistance in pediatric Ph-like ALL Cancer Research 2016, 76: pr11-pr11. DOI: 10.1158/1538-7445.pedca15-pr11.
    • Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic LeukemiaChen Z, Geng H, Lowell C, Weiss A, Hunger S, Melnick A, Muschen M. Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia Blood 2015, 126: 3716-3716. DOI: 10.1182/blood.v126.23.3716.3716.
    • Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair InhibitorsSullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Blood 2015, 126: 50-50. DOI: 10.1182/blood.v126.23.50.50.
    • Circadian Clock Protein CRY Controls B-Cell Intrinsic ToleranceCao Q, Zhao X, Gery S, Chen Z, Deng R, Sun H, Lin D, Zhao Z, Said J, Li Q, Muschen M, Evans R, Koeffler H. Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance Blood 2015, 126: 1029-1029. DOI: 10.1182/blood.v126.23.1029.1029.
    • B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic SignalingChan L, Chen Z, Braas D, Geng H, Hurtz C, Shojaee S, Cazzaniga V, Ng C, Ernst T, Hochhaus A, Kornblau S, Cazzaniga G, Liu G, Milne T, Koeffler H, Armstrong S, Dickins R, Yamamoto K, Graeber T, Muschen M. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling Blood 2015, 126: 1255-1255. DOI: 10.1182/blood.v126.23.1255.1255.
    • IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL CellsLee J, Geng H, Chen Z, PARK E, Klemm L, Bailey C, Muschen M. IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells Blood 2015, 126: 1325-1325. DOI: 10.1182/blood.v126.23.1325.1325.
    • Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center FormationDeng R, Hurtz C, Yue C, Xiao G, Yu H, Muschen M, Forman S, Martin P, Zeng D. Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation Blood 2015, 126: 1875-1875. DOI: 10.1182/blood.v126.23.1875.1875.
    • CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic LeukemiaLee J, Chen Z, Geng H, Xiao G, PARK E, Parekh S, Kornblau S, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia Blood 2015, 126: 1434-1434. DOI: 10.1182/blood.v126.23.1434.1434.
    • Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic LeukemiaKlemm L, Klemm L, Swaminathan S, Swaminathan S, Papaemmanuil E, Papaemmanuil E, Ford A, Ford A, Greaves M, Greaves M, Casellas R, Casellas R, Schatz D, Lieber M, Lieber M, Muschen M. Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia Blood 2015, 126: 166-166. DOI: 10.1182/blood.v126.23.166.166.
    • Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10Gang E, Hsieh Y, Kim H, Duchartre Y, Stephanie S, Muschen M, Wayner E, Heisterkamp N, Bonig H, Kim Y. Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10 Blood 2015, 126: 2525-2525. DOI: 10.1182/blood.v126.23.2525.2525.
    • Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic LeukemiaShi C, Han L, Zhang Q, Roberts K, Park E, Tabe Y, Jacamo R, Mu H, Wu S, Zhou J, Ma H, Zeng Z, Jain N, Jabbour E, Muschen M, Tasian S, Mullighan C, Weinstock D, Fruman D, Konopleva M. Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia Blood 2015, 126: 2529-2529. DOI: 10.1182/blood.v126.23.2529.2529.
    • Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic LeukemiaLi Q, Hurtz C, Shojaee S, Chen Z, Geng H, Xiao G, Loh M, Ye B, Melnick A, Muschen M. Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia Blood 2015, 126: 556-556. DOI: 10.1182/blood.v126.23.556.556.
    • PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic LeukemiaGang X, Geng H, Chan L, Chen Z, Jiang X, Muschen M. PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2015, 126: 902-902. DOI: 10.1182/blood.v126.23.902.902.
    • Abstract 2075: Signaling thresholds and negative B cell selection in acute lymphoblastic leukemiaChen Z, Shojaee S, Buchner M, Geng H, Lee J, Klemm L, Park E, Tan Y, Satterthwaite A, Paietta E, Hunger S, Loh M, Jung J, Coligan J, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell C, Müschen M. Abstract 2075: Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia 2015, 2075-2075. DOI: 10.1158/1538-7445.am2015-2075.
    • Abstract 4944: Identification of B-cell lymphoma 6 as a novel therapeutic target in glioblastomaChen Y, Xu L, Hazawa M, Thippeswamy A, Yang H, Müschen M, Lin D, Koeffler P. Abstract 4944: Identification of B-cell lymphoma 6 as a novel therapeutic target in glioblastoma 2015, 4944-4944. DOI: 10.1158/1538-7445.am2015-4944.
    • IFITM3 (CD225) Regulates CD19 Surface Expression and CD19-Mediated Activation of PI3K Signaling in Pre-B Acute Lymphoblastic Leukemia CellsLee J, Geng H, Chen Z, Park E, Park A, Klemm L, Bailey C, Muschen M. IFITM3 (CD225) Regulates CD19 Surface Expression and CD19-Mediated Activation of PI3K Signaling in Pre-B Acute Lymphoblastic Leukemia Cells Blood 2014, 124: 1070-1070. DOI: 10.1182/blood.v124.21.1070.1070.
    • Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast CrisisXiao G, Geng H, Chan L, Chen Z, Muschen M. Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast Crisis Blood 2014, 124: 3128-3128. DOI: 10.1182/blood.v124.21.3128.3128.
    • BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic LeukemiaHurtz C, Geng H, Xiao G, Loh M, Ye B, Melnick A, Muschen M. BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia Blood 2014, 124: 3570-3570. DOI: 10.1182/blood.v124.21.3570.3570.
    • Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor CellsNieborowska-Skorska M, Sullivan K, Podszywalow-Bartnicka P, Hoser G, Bolton-Gillespie E, Cramer-Morales K, Slupianek A, Zhou C, Cerny-Reiterer S, Stoklosa T, Sykes S, Valent P, Civin C, Muschen M, Minden M, Eppert K, Skorski T. Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells Blood 2014, 124: 480-480. DOI: 10.1182/blood.v124.21.480.480.
    • BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven LeukemiaPark E, Swaminathan S, Sadiyah M, Igarashi K, Melnick A, Muschen M. BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia Blood 2014, 124: 513-513. DOI: 10.1182/blood.v124.21.513.513.
    • Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic LeukemiaChan L, Braas D, Hurtz C, Shojaee S, Kharabi Masouleh B, Geng H, Ernst T, Hochhaus A, Graeber T, Muschen M. Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2014, 124: 783-783. DOI: 10.1182/blood.v124.21.783.783.
    • Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic LeukemiaSeyedmehdi S, Chen Z, Buchner M, Hurtz C, Geng H, Schjerven H, Chan L, Koeffler P, Willman C, Hunger S, Dovat S, Paietta E, Hofmann W, Melnick A, Alexander W, Kornblau S, Muschen M. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood 2014, 124: 787-787. DOI: 10.1182/blood.v124.21.787.787.
    • IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic LeukemiaGeng H, Lee J, Chen Z, Kharabi Masouleh B, Hurtz C, Park E, Xiao G, Parekh S, Kornblau S, Melnick A, Paietta E, Muschen M. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia Blood 2014, 124: 788-788. DOI: 10.1182/blood.v124.21.788.788.
    • FOXM1 Mediates Drug-Resistance and Represents a Therapeutic Target in Pre-B Acute Lymphoblastic LeukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. FOXM1 Mediates Drug-Resistance and Represents a Therapeutic Target in Pre-B Acute Lymphoblastic Leukemia Blood 2014, 124: 790-790. DOI: 10.1182/blood.v124.21.790.790.
    • Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic LeukemiaChen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell C, Paietta E, Willman C, Carroll W, Melnick A, Jung J, Jumaa H, Coligan J, Bolland S, Mak T, Muschen M. Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood 2014, 124: 792-792. DOI: 10.1182/blood.v124.21.792.792.
    • Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic LeukemiaSwaminathan S, Swaminathan S, Klemm L, Klemm L, Park E, Park E, Ford A, Ford A, Kweon S, Kweon S, Trageser D, Trageser D, Hasselfeld B, Hasselfeld B, Henke N, Henke N, Geng H, Geng H, Schwarz K, Schwarz K, Casellas R, Casellas R, Schatz D, Lieber M, Lieber M, Papaemmanuil E, Papaemmanuil E, Greaves M, Greaves M, Muschen M. Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic Leukemia Blood 2014, 124: 861-861. DOI: 10.1182/blood.v124.21.861.861.
    • The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic LeukemiaLee J, Buchner M, Geng H, Swaminathan S, Park E, Park A, Lin-Chao S, So C, Muschen M. The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic Leukemia Blood 2014, 124: 3777-3777. DOI: 10.1182/blood.v124.21.3777.3777.
    • PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B CellsShojaee S, Cazzaniga V, Schjerven H, Buchner M, Hurtz C, Geng H, Hochhaus A, Cazzaniga G, Melnick A, Kornblau S, Graeber T, Muschen M. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells Blood 2014, 124: 262-262. DOI: 10.1182/blood.v124.21.262.262.
    • Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic LeukemiaGeng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan L, Yu J, Tyner J, Chang B, Kornblau S, Bijl J, Ye B, Paietta E, Melnick A, Roeder R, Hunger S, Loh M, Milne T, Muschen M. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood 2014, 124: 284-284. DOI: 10.1182/blood.v124.21.284.284.
    • Abstract 2447: Lineage-specific metabolic reprogramming in BCR-ABL1-driven leukemiaChan L, Shojaee S, Hurtz C, Geng H, Ng C, Kharabi B, Müschen M. Abstract 2447: Lineage-specific metabolic reprogramming in BCR-ABL1-driven leukemia 2014, 2447-2447. DOI: 10.1158/1538-7445.am2014-2447.
    • Abstract 484: Identification of FOXM1 as therapeutic target in Philadelphia chromosome-positive acute lymphoblastic leukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Müschen M. Abstract 484: Identification of FOXM1 as therapeutic target in Philadelphia chromosome-positive acute lymphoblastic leukemia 2014, 484-484. DOI: 10.1158/1538-7445.am2014-484.
    • Abstract 510: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemiaSun H, Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Masouleh K, Müschen M, Koeffler H. Abstract 510: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia 2014, 510-510. DOI: 10.1158/1538-7445.am2014-510.
    • Biology and targeting options for kinase signaling in acute lymphoblastic leukemiaShojaee S, Muschen M. Biology and targeting options for kinase signaling in acute lymphoblastic leukemia AACR Education Book 2014, 2014: 91. DOI: 10.1158/aacr.edb-14-1332.
    • BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid LeukemiaPan R, Debose L, Benito J, Golfman L, Zweidler-McKay P, Han L, Harutyunyan K, Mu H, Ruvolo V, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian H, Ruvolo P, Andreeff M, Konopleva M. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia Blood 2013, 122: 1456-1456. DOI: 10.1182/blood.v122.21.1456.1456.
    • Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic LeukemiaBuchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia Blood 2013, 122: 1250-1250. DOI: 10.1182/blood.v122.21.1250.1250.
    • Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic LeukemiaKim E, Koehrer S, Rosin N, Wang Z, Thomas D, Ravandi F, Kornblau S, Kantarjian H, O'Brien S, Estrov Z, Buggy J, Muschen M, Davis R, Burger J. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia Blood 2013, 122: 1399-1399. DOI: 10.1182/blood.v122.21.1399.1399.
    • Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive LeukemiasDasgupta Y, Koptyra M, Nieborowska-Skorska M, Gillespie E, Stoklosa T, Hoser G, Wasik M, Muschen M, Richardson C, Skorski T. Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias Blood 2013, 122: 1466-1466. DOI: 10.1182/blood.v122.21.1466.1466.
    • Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199Konopleva M, Benito J, Harutyunyan K, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy J, Bendall L, Zweidler-McKay P, Coombes K, Qiu Y, Zhang N, Leverson J, Thomas D, O'Brien S, Kantarjian H, Kornblau S, Andreeff M. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 Blood 2013, 122: 3919-3919. DOI: 10.1182/blood.v122.21.3919.3919.
    • Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALLHurtz C, Geng H, Ballabio E, Xiao G, Ng C, Masouleh B, Willman C, Armstrong S, Milne T, Melnick A, Muschen M. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL Blood 2013, 122: 72-72. DOI: 10.1182/blood.v122.21.72.72.
    • Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor CellsNieborowska-Skorska M, Slupianek A, Hoser G, Bolton-Gillespie E, Tulin A, Cerny-Reiterer S, Valent P, Muschen M, Sykes S, Skorski T. Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells Blood 2013, 122: 810-810. DOI: 10.1182/blood.v122.21.810.810.
    • The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALLMasouleh B, Geng H, Hurtz C, Huang C, Chan L, Swaminathan S, Sun H, Koeffler H, Melnick A, Paietta E, Glimcher L, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL Blood 2013, 122: 836-836. DOI: 10.1182/blood.v122.21.836.836.
    • Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALLLee J, Geng H, Chen Z, Park E, Klemm L, Bailey C, Muschen M. Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL Blood 2013, 122: 2505-2505. DOI: 10.1182/blood.v122.21.2505.2505.
    • Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B CellsLee J, Buchner M, Geng H, Swaminathan S, Park E, Klemm L, Lin-Chao S, So C, Muschen M. Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells Blood 2013, 122: 2506-2506. DOI: 10.1182/blood.v122.21.2506.2506.
    • Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage LeukemiaChen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell C, Paietta E, Willman C, Carroll W, Melnick A, Jung J, Jumaa H, Coligan J, Bolland S, Mak T, Muschen M. Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia Blood 2013, 122: 229-229. DOI: 10.1182/blood.v122.21.229.229.
    • Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic LeukemiaGeng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan L, Masouleh B, Sykes D, Melnick A, Roeder R, Milne T, Muschen M. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood 2013, 122: 349-349. DOI: 10.1182/blood.v122.21.349.349.
    • Abstract A55: Induced hyperactivation of Ras-MAPK in chronic myeloid leukemia: role of negative feedback signalingSilveira V, Shojaee S, Müschen M. Abstract A55: Induced hyperactivation of Ras-MAPK in chronic myeloid leukemia: role of negative feedback signaling Cancer Research 2013, 73: a55-a55. DOI: 10.1158/1538-7445.fbcr13-a55.
    • Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL.Shojaee S, Buchner M, Gery S, Geng H, Chan L, Melnick A, Koeffler P, Müschen M. Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL. Cancer Research 2013, 73: 2334-2334. DOI: 10.1158/1538-7445.am2013-2334.
    • Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic LeukemiaSwaminathan S, Swaminathan S, Klemm L, Klemm L, Ford A, Ford A, Schwarz K, Schwarz K, Casellas R, Casellas R, Hennighausen L, Hennighausen L, Geng H, Geng H, Schatz D, Lieber M, Lieber M, Greaves M, Greaves M, Muschen M. Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia Blood 2012, 120: 519-519. DOI: 10.1182/blood.v120.21.519.519.
    • Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALLGeng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner J, Chang B, Titz B, Buchner M, Hurtz C, Graeber T, Druker B, Paietta E, Melnick A, Willman C, Carroll W, Muschen M. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood 2012, 120: 528-528. DOI: 10.1182/blood.v120.21.528.528.
    • Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALLHurtz C, Ramezani-Rad P, Geng H, Kharabi B, Carroll W, Willman C, Armstrong S, Melnick A, Muschen M. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL Blood 2012, 120: 776-776. DOI: 10.1182/blood.v120.21.776.776.
    • SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic LeukemiaRamezani-Rad P, Geng H, Chan L, Hurtz C, Jumaa H, Melnick A, Paietta E, Carroll W, Willman C, Lefebvre V, Muschen M. SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia Blood 2012, 120: 863-863. DOI: 10.1182/blood.v120.21.863.863.
    • Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALLMasouleh B, Hurtz C, Geng H, Ramezani-Rad P, Glimcher L, Muschen M. Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL Blood 2012, 120: 872-872. DOI: 10.1182/blood.v120.21.872.872.
    • Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALLBuchner M, Klemm L, Zhengshan C, Geng H, Muschen M. Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL Blood 2012, 120: 874-874. DOI: 10.1182/blood.v120.21.874.874.
    • BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor SurveillanceSwaminathan S, Kang H, Harvey R, Huang C, Buchner M, Chen Z, Geng H, Hall A, Igarashi K, Carroll W, Willman C, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance Blood 2012, 120: 1300-1300. DOI: 10.1182/blood.v120.21.1300.1300.
    • BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid LeukemiaShojaee S, Geng H, Gearhart M, Bardwell V, Muschen M. BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia Blood 2012, 120: 1301-1301. DOI: 10.1182/blood.v120.21.1301.1301.
    • Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine KinasesShojaee S, Buchner M, Swaminathan S, Geng H, Chan L, Bothe M, Chen Z, Melnick A, Molkentin J, Martin G, Koeffler H, Muschen M. Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases Blood 2012, 120: 1352-1352. DOI: 10.1182/blood.v120.21.1352.1352.
    • ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALLChen Z, Geng H, Buchner M, Klemm L, Hemati K, Shojaee S, Tak M, Coligan J, Carroll W, Willman C, Muschen M. ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL Blood 2012, 120: 291-291. DOI: 10.1182/blood.v120.21.291.291.
    • Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.Chen Z, Geng H, Klemm L, Buchner M, Hemati K, Shojaee S, Alexander W, Carroll W, Willman C, Muschen M. Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood 2012, 120: 2563-2563. DOI: 10.1182/blood.v120.21.2563.2563.
    • Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.Gang E, Hsieh Y, Geng H, Pham J, Muschen M, de Arcangelis A, Willman C, Carroll W, Georges-Labouesse E, Bonig H, Kim Y. Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. Blood 2012, 120: 2565-2565. DOI: 10.1182/blood.v120.21.2565.2565.
    • Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast CrisisChan L, Geng H, Muschen M. Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis Blood 2012, 120: 34-34. DOI: 10.1182/blood.v120.21.34.34.
    • BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox GenesCao Q, Gery S, Shojaee S, Gearhart M, Bardwell V, Muschen M, Koeffler H. BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes Blood 2012, 120: 3445-3445. DOI: 10.1182/blood.v120.21.3445.3445.
    • YM155 sensitivity in pediatric acute lymphoblastic leukemia.Chang B, Jemal A, Tyner J, Thayer M, Muschen M, Druker B. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal Of Clinical Oncology 2012, 30: 9555-9555. DOI: 10.1200/jco.2012.30.15_suppl.9555.
    • Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignanciesShojaee S, Buchner M, Swaminathan S, Chan L, Bothe M, Geng H, Melnick A, Molkentin J, Martin G, Koeffler P, Muschen M. Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies Cancer Research 2012, 72: 2944-2944. DOI: 10.1158/1538-7445.am2012-2944.
    • V(D)J RecombinationMüschen M. V(D)J Recombination 2012, 1-5. DOI: 10.1007/978-3-642-27841-9_6171-2.
    • Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic LeukemiaBicocca V, Chang B, Muschen M, Druker B, Tyner J. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia Blood 2011, 118: 2466-2466. DOI: 10.1182/blood.v118.21.2466.2466.
    • Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic LeukemiaJemal A, Tyner J, Thayer M, Muschen M, Druker B, Chang B. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia Blood 2011, 118: 2490-2490. DOI: 10.1182/blood.v118.21.2490.2490.
    • Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven LeukemiasShojaee S, Buchner M, Geng H, Silvia B, Koeffler P, Muschen M. Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias Blood 2011, 118: 1382-1382. DOI: 10.1182/blood.v118.21.1382.1382.
    • Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYCNahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Jumaa H, Ye B, Melnick A, Muschen M. Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC Blood 2011, 118: 1406-1406. DOI: 10.1182/blood.v118.21.1406.1406.
    • DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell SurvivalShojaee S, Buchner M, Geng H, Melnick A, Gery S, Molkentin J, Koeffler P, Muschen M. DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival Blood 2011, 118: 1479-1479. DOI: 10.1182/blood.v118.21.1479.1479.
    • Mechanisms of Ikaros-Mediated Tumor SuppressionNahar R, Ramezani-Rad P, Dovat S, Buchner M, Graeber T, Muschen M. Mechanisms of Ikaros-Mediated Tumor Suppression Blood 2011, 118: 408-408. DOI: 10.1182/blood.v118.21.408.408.
    • BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid LeukemiaHurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller M, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker B, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood 2011, 118: 446-446. DOI: 10.1182/blood.v118.21.446.446.
    • BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic LeukemiaSwaminathan S, Huang C, Titz B, Buchner M, Geng H, Graeber T, Willman C, Igarashi K, Melnick A, Muschen M. BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia Blood 2011, 118: 562-562. DOI: 10.1182/blood.v118.21.562.562.
    • Infectious Origins of Childhood LeukemiaKlemm L, Klemm L, Swaminathan S, Swaminathan S, Ford A, Ford A, Schwarz K, Schwarz K, Schatz D, Lieber M, Lieber M, Greaves M, Greaves M, Muschen M. Infectious Origins of Childhood Leukemia Blood 2011, 118: 751-751. DOI: 10.1182/blood.v118.21.751.751.
    • Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells in vitro and in vivoNguyen T, Attkisson E, Dai Y, Kramer L, Muschen M, Grant S. Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cells in vitro and in vivo Cancer Research 2011, 71: 2572-2572. DOI: 10.1158/1538-7445.am2011-2572.
    • Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibitionDuy C, Hurtz C, Koeffler P, Melnick A, Müschen M. Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition Cancer Research 2011, 71: lb-235-lb-235. DOI: 10.1158/1538-7445.am2011-lb-235.
    • Abstract LB-25: Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signalingRubbi L, Titz B, Brown L, Glavan E, Komisopoulou E, Chen S, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber T. Abstract LB-25: Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling Cancer Research 2011, 71: lb-25-lb-25. DOI: 10.1158/1538-7445.am2011-lb-25.
    • V(D)J RecombinationMüschen M. V(D)J Recombination 2011, 3875-3879. DOI: 10.1007/978-3-642-16483-5_6171.
    • WNT/β-Catenin Signaling in LeukemiaMüschen M. WNT/β-Catenin Signaling in Leukemia 2010, 129-142. DOI: 10.1007/978-1-4419-8023-6_6.
    • IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell ReceptorNahar R, Ramezani-Rad P, Duy C, Dovat S, Ye B, Melnick A, Muschen M. IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor Blood 2010, 116: 146-146. DOI: 10.1182/blood.v116.21.146.146.
    • Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic LeukemiaDuy C, Nowak D, Klemm L, Nahar R, Ng C, Elliott E, Hofmann W, Heisterkamp N, Lowell C, Koeffler P, Muschen M. Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia Blood 2010, 116: 147-147. DOI: 10.1182/blood.v116.21.147.147.
    • IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood LeukemiaSwaminathan S, Swaminathan S, Klemm L, Klemm L, Kweon S, Kweon S, Ford A, Ford A, Schwarz K, Schwarz K, Casellas R, Casellas R, Hennighausen L, Hennighausen L, Schatz D, Lieber M, Lieber M, Greaves M, Greaves M, Muschen M. IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia Blood 2010, 116: 26-26. DOI: 10.1182/blood.v116.21.26.26.
    • BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid LeukemiaHurtz C, Duy C, Cerchietti L, Chatzi K, Park E, Klemm L, Kim Y, Kahn M, Braig M, Muller M, Hochhaus A, Ye B, Melnick A, Muschen M. BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia Blood 2010, 116: 202-202. DOI: 10.1182/blood.v116.21.202.202.
    • VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL)Miles R, Downie J, Jahromi M, Joshi D, Rodic V, Muschen M, Yang J, Evans W, Meeker N, Trede N, Frazer J, Barnette P, Schiffman J. VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL) Blood 2010, 116: 273-273. DOI: 10.1182/blood.v116.21.273.273.
    • Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic LeukemiaNahar R, Trageser D, Klemm L, Duy C, Hofmann W, Park E, Kim Y, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia Blood 2010, 116: 274-274. DOI: 10.1182/blood.v116.21.274.274.
    • Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor GenesIwanski G, Thoennissen N, Nakitandwe J, Lin P, Kawamata N, Nahar R, Ramezani-Rad P, Chen S, Shurtleff S, Nowak D, Ruckert C, Dugas M, Bokemeyer C, Fazio G, Biondi A, Cazzaniga G, Downing J, Müschen M, Koeffler H. Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor Genes Blood 2010, 116: 3231-3231. DOI: 10.1182/blood.v116.21.3231.3231.
    • Targeting Survivin In Recalcitrant Acute Lymphoblastic LeukemiaPark E, Jiang E, Hsieh Y, Klemm L, Duy C, Conway E, Pelus L, Crispino J, Loh M, Kang E, Koo H, Yang A, Heisterkamp N, Kahn M, Muschen M, Kim Y. Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia Blood 2010, 116: 3263-3263. DOI: 10.1182/blood.v116.21.3263.3263.
    • Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-CateninJiang E, Park E, Nguyen C, Yoon J, Hsieh Y, Loh M, Muschen M, Kahn M, Kim Y. Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin Blood 2010, 116: 3264-3264. DOI: 10.1182/blood.v116.21.3264.3264.
    • SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic TargetNg C, Nahar R, Elliott E, Lowell C, Muschen M. SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target Blood 2010, 116: 4199-4199. DOI: 10.1182/blood.v116.21.4199.4199.
    • The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid LeukemiaShojaee S, Garcia C, Wu H, Muschen M. The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia Blood 2010, 116: 513-513. DOI: 10.1182/blood.v116.21.513.513.
    • ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic LeukemiaBicocca V, Chang B, Muschen M, Druker B, Tyner J. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia Blood 2010, 116: 539-539. DOI: 10.1182/blood.v116.21.539.539.
    • Adjuvant CD49d Blockade Eradicates Chemoresistant ALLHsieh Y, Park E, Jiang E, Dauber K, Chudziak D, Schaefer P, Klemm L, Scharman C, Kang E, Koo H, Loh M, Hofmann W, Heisterkamp N, Muschen M, Shimada H, Bonig H, Kim Y. Adjuvant CD49d Blockade Eradicates Chemoresistant ALL Blood 2010, 116: 869-869. DOI: 10.1182/blood.v116.21.869.869.
    • Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1-Driven B Cell Lineage Acute Lymphoblastic Leukemia.Gruber T, Chang M, Sposto R, Müschen M. Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1-Driven B Cell Lineage Acute Lymphoblastic Leukemia. Blood 2009, 114: 181-181. DOI: 10.1182/blood.v114.22.181.181.
    • BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.Duy C, Cerchietti L, Yu J, Ci W, Swaminathan S, Nahar R, Kweon S, Klemm L, Ye B, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood 2009, 114: 765-765. DOI: 10.1182/blood.v114.22.765.765.
    • BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.Duy C, Yu J, Swaminathan S, Nahar R, Kweon S, Polo J, Valls E, Klemm L, Cerchietti L, von Levetzow G, Herzog S, Jumaa H, de Alborán I, Melnick A, Ye B, Müschen M. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood 2009, 114: 91-91. DOI: 10.1182/blood.v114.22.91.91.
    • IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.Iacobucci I, Messina M, Iraci N, Lonetti A, Chiaretti S, Ferrari A, Papayannidis C, Messa F, Vitale A, Paoloni F, Cilloni D, Storlazzi C, Ottaviani E, Paolini S, Durante S, Soverini S, Guarini R, Vignetti M, Pane F, Saglio G, Foà R, Muschen M, Pfifer H, Ottmann O, Perini G, Baccarani M, Martinelli G. IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. Blood 2009, 114: 912-912. DOI: 10.1182/blood.v114.22.912.912.
    • Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia.Park E, Jiang E, von Levetzow G, Duy C, Klemm L, Hsieh Y, Kadavallore A, Ma H, Zhao Y, Nguyen C, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 10-10. DOI: 10.1182/blood.v114.22.10.10.
    • Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression.Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Muschen M, Sumerle L, Papayannidis C, Soverini S, Ottaviani E, Paolini S, Ferrari A, Messa F, Cilloni D, Vitale A, Pane F, Saglio G, Foà R, Baccarani M, Delledonne M, Martinelli G. Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression. Blood 2009, 114: 3074-3074. DOI: 10.1182/blood.v114.22.3074.3074.
    • PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.Iacobucci I, Papayannidis C, Paoloni F, Lonetti A, Muschen M, Vignetti M, Cilloni D, Soverini S, Messa F, Paolini S, Chiaretti S, Guadagnuolo V, Fazi P, Vitale A, Meloni G, Gobbi M, Malagola M, Saglio G, Pane F, Baccarani M, Foà R, Martinelli G. PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party. Blood 2009, 114: 12-12. DOI: 10.1182/blood.v114.22.12.12.
    • The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines.Nowak D, Kawamata N, Niebuhr B, Nowak V, Mossner M, Nahar R, Thoennissen N, Iwanski G, Stocking C, Dugas M, Hofmann W, Müschen M, Koeffler P. The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. Blood 2009, 114: 1284-1284. DOI: 10.1182/blood.v114.22.1284.1284.
    • Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species.Chang M, Wey S, Lee A, Müschen M. Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species. Blood 2009, 114: 1976-1976. DOI: 10.1182/blood.v114.22.1976.1976.
    • BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye B, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood 2009, 114: 2167-2167. DOI: 10.1182/blood.v114.22.2167.2167.
    • Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.Jiang E, Park E, Scharman C, Hsieh Y, Kadavallore A, Nguyen C, Zhao Y, McMillan M, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 3072-3072. DOI: 10.1182/blood.v114.22.3072.3072.
    • The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia.Klemm L, Duy C, Iacobucci I, von Levetzow G, Feldhahn N, Kim Y, Hofmann W, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber M, Casellas R, Müschen M. The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia. Blood 2009, 114: 3274-3274. DOI: 10.1182/blood.v114.22.3274.3274.
    • Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia.Duy C, Sprangers M, Klemm L, Nahar R, Nowak D, Martinelli G, Hofmann W, Koeffler P, Jumaa H, Müschen M. Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. Blood 2009, 114: 579-579. DOI: 10.1182/blood.v114.22.579.579.
    • Leukemia Stem CellsMüschen M. Leukemia Stem Cells 2009, 281-294. DOI: 10.1007/978-90-481-3040-5_13.
    • V(D)J RecombinationMüschen M. V(D)J Recombination 2009, 3160-3164. DOI: 10.1007/978-3-540-47648-1_6171.
    • Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1Trageser D, Duy C, Klemm L, Gruber T, Nahar R, Park E, Kim Y, Groffen J, Heisterkamp N, Hofmann W, Martinelli G, Williams R, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1 Blood 2008, 112: 15-15. DOI: 10.1182/blood.v112.11.15.15.
    • Obesity Accelerates T-Cell Leukemia in a Spontaneous Mouse Model.Yun J, Klemm L, Behan J, Müschen M, Mittelman S. Obesity Accelerates T-Cell Leukemia in a Spontaneous Mouse Model. Blood 2008, 112: 1909-1909. DOI: 10.1182/blood.v112.11.1909.1909.
    • The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression.Nahar R, Trageser D, Klemm L, Duy C, van Essen P, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jack H, Jumaa H, Muschen M. The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression. Blood 2008, 112: 1918-1918. DOI: 10.1182/blood.v112.11.1918.1918.
    • Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALLJiang E, Yu M, Hsieh Y, DeLaTorre B, Kadavallore A, Scharman C, Park E, Yang A, Muschen M, Groffen J, Heisterkamp N, Kim Y. Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL Blood 2008, 112: 2922-2922. DOI: 10.1182/blood.v112.11.2922.2922.
    • Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell ReceptorDuy C, Klemm L, Nahar R, van Essen P, Sprangers M, Kim Y, Park E, Martinelli G, Heisterkamp N, Hofmann W, Jumaa H, Muschen M. Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor Blood 2008, 112: 294-294. DOI: 10.1182/blood.v112.11.294.294.
    • BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic LeukemiaDuy C, Yu J, Cerchietti L, Klemm L, Nahar R, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jumaa H, Melnick A, Ye B, Muschen M. BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia Blood 2008, 112: 295-295. DOI: 10.1182/blood.v112.11.295.295.
    • Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic HypermutationKlemm L, Duy C, Feldhahn N, Groffen J, Kim Y, Hofmann W, Jumaa H, Lieber M, Casellas R, Muschen M. Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic Hypermutation Blood 2008, 112: 571-571. DOI: 10.1182/blood.v112.11.571.571.
    • The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cellsMelchior K, Weiß J, Zaehres H, Kim Y, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells Biological Chemistry 2008, 0: 080808064026415-22. DOI: 10.1515/bc.2008.108_bchm.just-accepted.
    • PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia.Klemm L, Feldhahn N, Hoffmann T, Hofmann W, Jumaa H, Muschen M. PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia. Blood 2007, 110: 1005-1005. DOI: 10.1182/blood.v110.11.1005.1005.
    • Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1.Trageser D, Klemm L, Herzog S, Kim Y, Duy C, Hofmann W, Groffen J, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1. Blood 2007, 110: 2795-2795. DOI: 10.1182/blood.v110.11.2795.2795.
    • The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells.Duy C, de Alboran I, Jumaa H, Muschen M. The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells. Blood 2007, 110: 797-797. DOI: 10.1182/blood.v110.11.797.797.
    • Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.Kim Y, Park E, Lorentzen C, De La Torre B, Hsieh Y, Whang H, Klemm L, Nguyen C, McMillan M, Teo J, Muschen M, Kahn M. Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia. Blood 2007, 110: 1596-1596. DOI: 10.1182/blood.v110.11.1596.1596.
    • Activation-Induced Cytidine Deaminase Acts as a Mutator in BCR-ABL1-Transformed Acute Lymphoblastic Leukemia Cells.Feldhahn N, Klein F, Hofmann W, Rowley J, Jumaa H, Müschen M. Activation-Induced Cytidine Deaminase Acts as a Mutator in BCR-ABL1-Transformed Acute Lymphoblastic Leukemia Cells. Blood 2006, 108: 640-640. DOI: 10.1182/blood.v108.11.640.640.
    • The BCR-ABL1 Kinase Interferes with Pre-B Cell Receptor Signal Transduction in B Cell Precursor Leukemia Cells.Klein F, Feldhahn N, Wernet P, Müschen M. The BCR-ABL1 Kinase Interferes with Pre-B Cell Receptor Signal Transduction in B Cell Precursor Leukemia Cells. Blood 2004, 104: 1894-1894. DOI: 10.1182/blood.v104.11.1894.1894.
    • Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion and IGL Gene Rearrangement.Klein F, Feldhahn N, Mooster J, Wernet P, Müschen M. Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion and IGL Gene Rearrangement. Blood 2004, 104: 315-315. DOI: 10.1182/blood.v104.11.315.315.
    • Aberrantly regulated genes in TEL/AML1 positive leukaemiaHentschel U, Feldhahn N, Berthold F, Müschen M, Fischer M. Aberrantly regulated genes in TEL/AML1 positive leukaemia Klinische Pädiatrie 2004, 216 DOI: 10.1055/s-2004-828574.
    • CD95 ligand expression mediates immune escape in breast cancerMoers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression mediates immune escape in breast cancer Breast Cancer Research 2001, 3: a76. PMCID: PMC3300589, DOI: 10.1186/bcr406.
    • Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 geneMoers C, Müschen M, Beckmann M, Mallmann P. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene Breast Cancer Research 2001, 3: a77. PMCID: PMC3300590, DOI: 10.1186/bcr407.
    • CD95 ligand expression in dedifferentiated breast cancerMoers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression in dedifferentiated breast cancer Breast Cancer Research 2001, 3: a75. PMCID: PMC3300588, DOI: 10.1186/bcr405.
    • CD95 ligand induced apoptosis as a mechanism of intrahepatic immunoregulationMüschen M, Warskulat U, Häussinger D. CD95 ligand induced apoptosis as a mechanism of intrahepatic immunoregulation Journal Of Hepatology 1998, 28: 47. DOI: 10.1016/s0168-8278(98)80395-4.